CN102028746B - Drug for treating coronary heart disease and extraction method - Google Patents
Drug for treating coronary heart disease and extraction method Download PDFInfo
- Publication number
- CN102028746B CN102028746B CN200910070686.0A CN200910070686A CN102028746B CN 102028746 B CN102028746 B CN 102028746B CN 200910070686 A CN200910070686 A CN 200910070686A CN 102028746 B CN102028746 B CN 102028746B
- Authority
- CN
- China
- Prior art keywords
- extract
- alcohol
- ethanol
- adds
- concentrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000605 extraction Methods 0.000 title claims abstract description 93
- 239000003814 drug Substances 0.000 title claims abstract description 79
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 74
- 229940079593 drug Drugs 0.000 title claims abstract description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 1017
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 106
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 106
- 238000002360 preparation method Methods 0.000 claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 230000000694 effects Effects 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims description 320
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 claims description 143
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 132
- 229910001868 water Inorganic materials 0.000 claims description 124
- 239000003480 eluent Substances 0.000 claims description 122
- 238000010828 elution Methods 0.000 claims description 115
- 238000010992 reflux Methods 0.000 claims description 110
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 claims description 105
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 claims description 105
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 claims description 105
- 239000000706 filtrate Substances 0.000 claims description 103
- 239000011347 resin Substances 0.000 claims description 102
- 229920005989 resin Polymers 0.000 claims description 102
- 239000007788 liquid Substances 0.000 claims description 99
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 claims description 81
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 claims description 81
- 230000002829 reductive effect Effects 0.000 claims description 65
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 58
- 238000001556 precipitation Methods 0.000 claims description 56
- 239000012567 medical material Substances 0.000 claims description 55
- 238000011282 treatment Methods 0.000 claims description 51
- -1 fatty acid ester Chemical class 0.000 claims description 50
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 48
- 238000001035 drying Methods 0.000 claims description 31
- 239000012141 concentrate Substances 0.000 claims description 30
- 239000006187 pill Substances 0.000 claims description 29
- 239000006071 cream Substances 0.000 claims description 28
- 238000001914 filtration Methods 0.000 claims description 28
- 239000006228 supernatant Substances 0.000 claims description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 27
- 238000000926 separation method Methods 0.000 claims description 27
- 239000003513 alkali Substances 0.000 claims description 26
- 238000002481 ethanol extraction Methods 0.000 claims description 23
- 238000002156 mixing Methods 0.000 claims description 22
- 238000004321 preservation Methods 0.000 claims description 20
- 239000008118 PEG 6000 Substances 0.000 claims description 17
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 17
- 229940057995 liquid paraffin Drugs 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 17
- 238000005406 washing Methods 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 8
- 230000002879 macerating effect Effects 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000001828 Gelatine Substances 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 4
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 3
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000007766 cera flava Substances 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 238000003808 methanol extraction Methods 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 2
- 241001072909 Salvia Species 0.000 abstract 2
- 235000017276 Salvia Nutrition 0.000 abstract 2
- 238000009776 industrial production Methods 0.000 abstract 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 36
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 27
- 235000008504 concentrate Nutrition 0.000 description 25
- 239000004615 ingredient Substances 0.000 description 19
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 16
- 230000006378 damage Effects 0.000 description 11
- 208000028867 ischemia Diseases 0.000 description 11
- 206010002383 Angina Pectoris Diseases 0.000 description 9
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 230000004089 microcirculation Effects 0.000 description 6
- 238000002137 ultrasound extraction Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 206010002660 Anoxia Diseases 0.000 description 4
- 241000976983 Anoxia Species 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000007953 anoxia Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 108010035766 P-Selectin Proteins 0.000 description 3
- 102100023472 P-selectin Human genes 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000008899 fufang danshen Substances 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- QOFLTGDAZLWRMJ-UHFFFAOYSA-N 2-methylpropane-1,1-diol Chemical compound CC(C)C(O)O QOFLTGDAZLWRMJ-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 102100033902 Endothelin-1 Human genes 0.000 description 2
- 101800004490 Endothelin-1 Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 208000025870 aspirin resistance Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000003154 D dimer Substances 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 206010038491 Renal papillary necrosis Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 108010052295 fibrin fragment D Proteins 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 230000006659 positive regulation of apoptotic process Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a drug for treating coronary heart disease and an extraction method. The extraction method comprises the following steps: extracting salvia with alcohol; adding a solvent to notoginseng; reflowing and extracting the mixture; and extracting dreg decoction of salvia and the like. The invention has the following advantages: the process route can realize industrialization and the quality is stable and controllable. Relevant experiments show that the drug has the advantages of high curative effect and product purity, good absorbability, stable quality and novel application compared with the prior art, and meanwhile, the preparation method is simple in process, convenient to operate, low in cost and suitable for industrial production.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of coronary heart disease, belong to the field of Chinese medicines.
Background technology
Along with growth in the living standard, world population ages and morbidity colony rejuvenation, Patients with geriatric cardiovascular and cerebrovascular diseases increases year by year, has become the second largest disease of harm humans health.Angina pectoris is a kind of caused by myocardium ischemia, anoxia, with ictal chest pain or the uncomfortable clinical syndrome for main manifestations of chest.Angina pectoris refers to the angina pectoris because coronary atherosclerosis or spasm cause caused by myocardial ischemia, anoxia, accounts for 90% of patient with angina pectoris.
The anginal method of current treatment is based on blood vessel dilating, reduction blood viscosity, anti-platelet aggregation, anticoagulation.Traditional Western medicine of application is nitrate, nitrous acid ester, beta-blocker, calcium antagonist etc., but all there is larger toxic and side effects, unsuitable long-term taking, mostly is symptomatic treatment and to course advancement without larger effect.Such as, occur sometimes after taking nitroglycerin beating in feeling of fullness in the head, head, palpitating speed, even faint [see new pharmacology (the 14th edition) 264 pages], find that there is again in recent years and cause severe hypotension [see contemporary Chinese medical journal 1997; 7 (4): 42; Shaanxi medical journal 1996; 25 (5): 315] toleration, is easily produced [see southern nursing magazine 1996; The problem such as 3 (5): 7 ~ 9], hinders its application clinically.
Although also there is the anginal Chinese patent medicine of many treatments, wherein ball, loose, cream, pellet, decoction become ancient history already, and modern seldom applies.The preparations such as common FUFANG DANSHEN PIAN and capsule are had to sell in the market, but conventional tablet, capsule manufacturing techniques fall behind, active constituent content is low, without quality control index, need oral through gastrointestinal absorption, absorbed into serum after liver generation first pass effect, bioavailability is low, absorbs slow. the need of the first aid of Patients With Angina Pectoris can not be applicable to.
FUFANG DANSHEN DIWAN is fast, the eutherapeutic therapeutic drug of coronary heart disease of a kind of special effect, clinically deeply by the welcome of patient.In order to improve the preparation technology of FUFANG DANSHEN DIWAN, the present inventor conducts in-depth research from extraction process aspect, from saving herb resource aspect, improves product yield, the comprehensive utilization ratio of effective ingredient contained by medical material.
Summary of the invention
The invention provides a kind of medicine for the treatment of coronary heart disease.
The medicine for the treatment of coronary heart disease of the present invention, described medicine is prepared from by the crude drug of following percentage by weight, Radix Salviae Miltiorrhizae 19.8%-97%, Radix Notoginseng 2%-80%, Borneolum Syntheticum 0.2%-3%, described preparation first crude drug is prepared into active constituents of medicine through following steps, then be prepared into medicine further.
Step 1, Radix Salviae Miltiorrhizae adds alcohol, extracts, and filters, and extracting solution concentrates, and leaves standstill, and filters, and precipitation is dry, obtains Part I Tanshinone I I A extract; Filtrate crosses resin, first uses low concentration alcohol eluting, then uses high concentration alcohol eluting, collects high concentration alcohol eluen, concentrated, leaves standstill, and filters, and precipitation is dry, obtains Part II tanshinone ⅡA extract, and two parts merge, and obtain Tanshinone I I A extract;
Step 2, gets step 1 Radix Salviae Miltiorrhizae alcohol extraction medicinal residues, extracts, and filters, and filtrate concentrates, and lets cool, add acid for adjusting pH value, cold preservation leaves standstill, and filter, filtrate crosses resin, washes with water successively, low concentration alcohol eluting, high concentration alcohol eluting, collects high concentration alcohol eluen, concentrated, dry, obtains salvianolic acid B extract;
Step 3, Radix Notoginseng adds solvent reflux, extract, extracting liquid filtering, and filtrate is concentrated into without alcohol taste, adding distil water, and upper macroporous resin, first washes with water, and eluent discards, then uses alcohol eluting, collects alcohol eluen, concentrated, dry, obtains Radix Notoginseng extract;
Step 4, the salvianolic acid B medicinal residues after step 2 alcohol extraction add, and aqueous alkali is or/and water extraction, and extracting solution concentrates, and adds alcohol, and leave standstill, supernatant concentration, obtains Radix Salviae Miltiorrhizae extractum;
Step 5, the Tanshinone I I A extract that step 1 obtains, the salvianolic acid B extract that step 2 obtains, the Radix Notoginseng extract that step 3 obtains, the Radix Salviae Miltiorrhizae extractum that step 4 obtains and Borneolum Syntheticum make drop pill further;
Wherein described in step 3, solvent is selected from: the methanol of water, aqueous slkali, 50-100%, ethanol, normal propyl alcohol, isopropyl alcohol, n-butyl alcohol or isobutanol.
Medicine of the present invention is for oral medicine, its preparation adopts the preparation of galenic pharmacy routine techniques, comprise the step mixed with the adjuvant of oral drugs by active constituents of medicine, wherein the adjuvant of oral drug preparation is selected from starch, amylum pregelatinisatum, dextrin, Icing Sugar, lactose, mannitol, calcium sulfate two water thing, calcium hydrogen phosphate, magnesium oxide, calcium carbonate, magnesium carbonate, water, ethanol, starch slurry, syrup, liquid glucose, maltose, refined honey, cane sugar powder, citric acid, essence, mucialga of arabic gummy, gelatine size, polyvinylpyrrolidone (PVP), rubber cement, microcrystalline Cellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, magnesium stearate, stearic acid, zinc stearate, calcium stearate, Pulvis Talci, Macrogol 4000, polyethylene glycol 6000, micropowder silica gel, vegetable oil, sodium stearate, glycerin gelatine, stearic acid, glyceryl monostearate, insect wax, one or several combinations of hydrogenated oil and fat.
Oral formulations of the present invention is selected from: all acceptable dosage forms on tablet, dispersible tablet, hard capsule, soft capsule, granule, pill, micropill, powder, drop pill, slow releasing preparation, controlled release preparation, syrup, oral liquid, soft extract and extractum pharmaceutics.
Its preferred preparation method of medicine that confession of the present invention is oral, step is:
Step 1, Radix Salviae Miltiorrhizae adds the alcohol extraction 1-10 hour of 2-20 times amount 60% ~ 100%, filters, medicinal residues 2-20 times amount 60% ~ 100% alcohol, extracts 1-10 hour, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 0.2-5 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I Tanshinone I I A extract; Macroporous resin (polar resin S-8, low pole Resin A B-8 or non-polar resin D101) on filtrate, 50-85% ethanol elution, eluent discards, use 85-100% ethanol elution again, collect eluent, be concentrated into alcohol content 65-85%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone ⅡA extract, two parts merge, and obtain tanshinone ⅡA extract;
Step 2, get step 1 Radix Salviae Miltiorrhizae alcohol extraction medicinal residues and add 2-20 times amount 10-100% alcohol extraction 0.5-10 hour, filter, remaining medicinal residues add 2-20 times amount 10-100% alcohol extraction 0.5-10 hour, filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to liquid PH value 1-4, leave standstill, filter, filtrate crosses macroporous resin (polar resin S-8, low pole Resin A B-8, non-polar resin D101 or polyamide), wash with water successively, low concentration alcohol eluting, high concentration alcohol eluting, collect high concentration alcohol eluen, concentrated, dry, obtain salvianolic acid B extract,
Step 3, Radix Notoginseng adds alcohol reflux 1-2 time of 2-20 times of 50-100%, each extraction time 0.5-10 hour, extracting liquid filtering, filtrate is concentrated into without alcohol taste, adds the distilled water of 1-3 times of medical material amount, upper macroporous resin (S-8, AB-8 or D101), first washes with water, eluent discards, use 30-100% methanol, ethanol, normal propyl alcohol, isopropyl alcohol, n-butyl alcohol or isobutanol eluting again, collect alcohol eluen, concentrated, drying, obtains Radix Notoginseng extract;
Step 4, the salvianolic acid B medicinal residues after the alcohol extraction of step 2, add the aqueous alkali of 2-12 times of pH value 7-10, extract 1-3 time, add 2-12 times of water again, extract 1-3 time, filter, filtrate concentrates, add ethanol to medicinal liquid alcohol content 50-80%, leave standstill, separation of supernatant, reclaim ethanol, receive cream to pol 50%-90% or concentrated, dry, pulverizing, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, by Tanshinone I I A extract obtained above, salvianolic acid B extract, Radix Notoginseng extract, Radix Salviae Miltiorrhizae extractum mixes with adjuvant with Borneolum Syntheticum, adds any one or more than one adjuvants, adjuvant addition is 1-6 times of active component, makes any one oral formulations;
Wherein described in step 1 and 2, alcohol is selected from: methanol, ethanol, normal propyl alcohol, isopropyl alcohol, n-butyl alcohol or isobutanol alcohol, and described extracting mode is selected from: the extraction of reflux, extract, warm macerating, merceration extraction, seepage pressure effects, supersound extraction, dynamic countercurrent extraction or microwave extraction.
The preferred drop pill of medicine of the present invention, its preparation adopts the preparation of galenic pharmacy routine techniques, and comprise the step mixed with the adjuvant of drop pill medicine by active constituents of medicine, described adjuvant is selected from fat-soluble substrate and water-soluble base, and the auxiliary ratio of medicine is 1: 1-6.Wherein said fat-soluble substrate is selected from: stearic acid, glyceryl monostearate, insect wax, Cera Flava, paraffin, hydrogenated vegetable oil, semi-synthetic fatty acid ester; Water-soluble base is selected from Polyethylene Glycol, polyoxyethylene monostearate, poloxamer, sodium stearate, glycerin gelatine etc.; Xylitol and composites of starch, erythritol; The auxiliary ratio of preferred medicine is 1: 4.0.
The preferred preparation method of drop pill of the present invention, step is:
Step 1, Radix Salviae Miltiorrhizae adds the alcohol extraction 1-8 hour of 2-15 times amount 60% ~ 100%, filters, the medicinal residues alcohol of 2-15 times amount 60% ~ 100%, extracts 1-8 hour, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 0.2-3 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I Tanshinone I I A extract; Macroporous resin (polar resin S-8, low pole Resin A B-8 or non-polar resin D101) on filtrate, 50-85% ethanol elution, eluent discards, use 85-100% ethanol elution again, collect eluent, be concentrated into alcohol content 65-85%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II Tanshinone I I A extract, two parts merge, and obtain tanshinone ⅡA extract;
Step 2, get step 1 Radix Salviae Miltiorrhizae alcohol extraction medicinal residues and add 2-15 times amount 10-90% alcohol extraction 1-8 hour, filter, remaining medicinal residues add 2-15 times amount 10-90% alcohol extraction 1-8 hour, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 1-3, leave standstill, filter, filtrate crosses macroporous resin (S-8, AB-8 or D101), wash with water successively, 5-20% second % alcohol eluting, finally uses 40-90% ethanol elution, collect 40-90% ethanol elution, concentrated, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds alcohol reflux 1-2 time of 2-10 times of 60-80%, each extraction time 0.5-3 hour, extracting liquid filtering, filtrate is concentrated into without alcohol taste, adds the distilled water of 1-3 times of medical material amount, upper macroporous resin (S-8, AB-8 or D101), first washes with water, eluent discards, use 30-60% ethanol elution again, collect alcohol eluen, concentrated, drying, obtains Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, the aqueous alkali that first time adds 2-12 times amount PH7-8 decocts 1-3 hour, and second time adds 2-12 times amount soak by water 0.5-2 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 50%-80%, leave standstill 12-36 hour, separation of supernatant, reclaim ethanol, receive cream to pol 55%-80%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone ⅡA extract of step 1, salvianolic acid B extract, Radix Notoginseng extract is suspended in the pre-PEG-6000 melted successively; Radix Salviae Miltiorrhizae extractum adds water mix homogeneously; Said two devices mix homogeneously; Add Borneolum Syntheticum again, mixing; Material temperature is 60-100 DEG C; The temperature of liquid paraffin is 0-10 DEG C, makes drop pill;
Wherein described in step 1 and 2, alcohol is selected from: methanol, ethanol, normal propyl alcohol, isopropyl alcohol, n-butyl alcohol or isobutanol alcohol, and described extracting mode is selected from: the extraction of reflux, extract, warm macerating, merceration extraction, seepage pressure effects, supersound extraction, dynamic countercurrent extraction or microwave extraction.
The preferred preparation method of drop pill of the present invention, step is:
Step 1, Radix Salviae Miltiorrhizae adds the alcohol reflux 1-5 hour of 2-10 times amount 80% ~ 100%, filters, the medicinal residues ethanol of 2-10 times amount 80% ~ 100%, reflux, extract, 1-5 hour, filters, and medicinal residues are used for salvianolic acid B and extract, filtrate is concentrated into 0.2-1 times of medical material amount, leaves standstill, and filters; Precipitation is dry, obtains Part I tanshinone ⅡA extract; Macroporous resin (S-8, AB-8 or D101) on filtrate, 60-85% ethanol elution, eluent discards, use 85-100% ethanol elution again, collect eluent, be concentrated into alcohol content 65-85%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone ⅡA extract, two parts merge, and obtain tanshinone ⅡA extract;
Step 2, get step 1 Radix Salviae Miltiorrhizae alcohol extraction medicinal residues and add 2-10 times amount 30-70% alcohol reflux 1-6 hour, filter, remaining medicinal residues add 2-10 times amount 30-70% alcohol reflux 1-6 hour, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to liquid PH value 1-3, leave standstill, filter, filtrate crosses macroporous resin (S-8, AB-8 or D101), wash with water successively, 10-20% ethanol elution, finally use 40-70% ethanol elution, collect 40-70% ethanol elution, concentrated, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds alcohol reflux 1-2 time of 5-10 times of 60-80%, each extraction time 0.5-3 hour, extracting liquid filtering, filtrate is concentrated into without alcohol taste, adds the distilled water of 1-3 times of medical material amount, upper macroporous resin (S-8, AB-8 or D101), first washes with water, eluent discards, use 40-60% ethanol elution again, collect alcohol eluen, concentrated, drying, obtains Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, the aqueous alkali that first time adds 6-12 times amount PH7-8 decocts 1-3 hour, and second time adds 6-12 times amount soak by water 0.5-2 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 50%-75%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 55%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone ⅡA extract of step 1, salvianolic acid B extract, Radix Notoginseng extract is suspended in the pre-PEG-6000 melted successively; Radix Salviae Miltiorrhizae extractum adds water mix homogeneously; Said two devices mix homogeneously; Add Borneolum Syntheticum again, mixing; Material temperature is 60-100 DEG C; The temperature of liquid paraffin is 0-10 DEG C, makes drop pill.
The particularly preferred preparation method of drop pill of the present invention, step is:
Step 1, Radix Salviae Miltiorrhizae adds the alcohol reflux 2 times of 3-5 times amount 95%, each 1-2 hour, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 0.2-0.6 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I Tanshinone I I A extract; Macroporous resin AB-8 on filtrate, 70% ethanol elution, eluent discards, then uses 95% ethanol elution, collect eluent, be concentrated into alcohol content 80%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone ⅡA extract, and two parts merge, and obtain tanshinone ⅡA extract;
Step 2, gets step 1 Radix Salviae Miltiorrhizae alcohol extraction medicinal residues, adds the alcohol reflux 2 times of 4-6 times amount 40-60%, each 1-2hr, filter, filtrate is concentrated into without alcohol, lets cool to less than 10 DEG C, add dilute hydrochloric acid adjust ph 1.8-2.0, cold preservation leaves standstill more than 12hr, filters, upper AB-8 macroporous resin eluting, first wash with water, eluent discards; Wash with 15% ethanol again, eluent discards; Finally wash with 50% ethanol, collect 50% ethanol elution, concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds the alcohol reflux 2 times of 5-10 times of 60-80%, each extraction time 1-2 hour, extracting liquid filtering, filtrate is concentrated into without alcohol taste, adds the distilled water of 1-3 times of medical material amount, upper macroporous resin AB-8, first wash with water, eluent discards, then uses 40-60% ethanol elution, collect alcohol eluen, concentrated, dry, obtain Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, the aqueous alkali that first time adds 6-12 times amount PH7-8 decocts 1-3 hour, and second time adds 8 times amount soak by water 1 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 60%-70%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 70%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone ⅡA extract of step 1, salvianolic acid B extract, Radix Notoginseng extract is suspended in the pre-PEG-6000 melted successively; Radix Salviae Miltiorrhizae extractum adds water mix homogeneously; Said two devices mix homogeneously; Add Borneolum Syntheticum again, mixing; Material temperature is 60-100 DEG C; The temperature of liquid paraffin is 5-10 DEG C, makes drop pill.
The present invention also comprises the application of medicinal dropping ball in the medicine of the cardiovascular disease such as preparation a kind of resisting coronary heart disease, angina pectoris by treatment coronary heart disease of the present invention.
The present invention is more more superior than prior art because the change of technique causes the present invention to treat the medicinal dropping ball of coronary heart disease.
Illustrate that the present invention treats the beneficial effect of the medicinal dropping ball of coronary heart disease below by way of experimental data.
Before Myocytes Anoxia, add the medicinal dropping ball for the treatment of coronary heart disease of the present invention, intracellular calcium fluorescence intensity obviously declines, and proves that the medicinal dropping ball for the treatment of coronary heart disease has antagonism myocardial cell calcium overload, the effect of protecting myocardial cell.
After myocardial ischemia-reperfusion, in tissue, high-energy phosphate compound obviously reduces, and lipid peroxide contents showed increased, causes reperfusion injury.Before ischemia during pre-filled and postischemic reperfusion time add treatment coronary heart disease medicinal dropping ball, in tissue, high-energy phosphate compound is all higher than ischemic reperfusion note group, two groups of adenosine triphosphate (ATP), cardiac muscular tissue's gland nucleoside total amount (TAN) are all close to normal level, and LPO levels is lower than ischemic reperfusion note group.This result proves, before ischemia during pre-filled and postischemic reperfusion time give to treat the medicinal dropping ball of coronary heart disease all by increasing cardiac energy deposit, the generation of anti-lipid peroxidation thing and protecting myocardial cell.
Cardiomyocyte cell death is damage type the most serious in myocardial ischemia-reperfusion, comprises necrocytosis and apoptosis.The regulation and control that apoptotic generation is expressed by several genes.Myocardial infarction rear section myocardial cell generation apoptosis, probably overloads with the cell calcium caused by ischemia relevant with Scavenging Oxygen Free Radical.The medicinal dropping ball for the treatment of coronary heart disease obviously can reduce apoptosis of cardiac muscle quantity after myocardial ischemia-reperfusion, reduces the myocardial infarct size of ischemia-reperfusion rat, significantly alleviates pathology damage degree, and stronger with the medicinal dropping ball dosage increasing effect for the treatment of coronary heart disease.Anoxia experiment display is carried out in cultured myocyte, the medicinal dropping ball intervention for the treatment of coronary heart disease obviously can be lowered apoptotic proteins Fas and be expressed, slight upregulation of apoptosis Profilin Bcl-2 expresses, and the medicinal dropping ball of display treatment coronary heart disease has certain influence to the protein expression of apoptosis-related genes in cell further.
The medicinal dropping ball for the treatment of coronary heart disease improves microcirculation albumin outside leakage and mast cell degranulation is one of important symbol of microcirculation disturbance.The improvement result of the treatment medicinal dropping ball induced by endotoxin of coronary heart disease and the microcirculation disturbance caused by ischemia-reperfusion, confirm that the medicinal dropping ball for the treatment of coronary heart disease improves significantly to the Rat Mesenteric Microcirculation obstacle that ischemia-reperfusion causes, show: the early stage albumin outside leakage of the ischemia that 1. Radix Salviae Miltiorrhizae can be suppressed not play a role; 2. effectively mast cell degranulation is suppressed; 3. the generation of vascular endothelial cell and leukocyte oxide is suppressed; 4. sticking of leukocyte and vascular endothelial cell is suppressed; 5. also impact is had to the interaction of the cell adhesion molecules after ischemia-reperfusion, peroxidating and leukocyte and endotheliocyte.
The medicinal dropping ball for the treatment of coronary heart disease on patient's bulbar Conjunctiva Microcirculation, thrombelastogram has more obviously affects, after medication, patient's arteriole vessel diameter is broadening, and fine vein blood vessel narrow diameter, arteriole blood flow rate and blood flow have to be increased more significantly.
Medicinal dropping ball antioxidation, antiinflammatory, the protection blood vessel endothelium for the treatment of coronary heart disease, suppress atherosclerotic plaque formation and the balance between neointimal hyperplasia vascular endothelial cell associated media nitric oxide (NO) and vasoconstrictive factor endothelin-1 (ET-1) etc. to maintain the stability of blood vessel.After damage, the medicinal dropping ball of the treatment coronary heart disease of variable concentrations all obviously alleviates human vascular endothelial damage caused by LPS, illustrates that the medicinal dropping ball for the treatment of coronary heart disease has obvious protective effect to vascular endothelial cell.The medicinal dropping ball of variable concentrations being treated coronary heart disease is used in the culture fluid before and after Hydroperoxide injury modeling, find that can balance NO at the medicinal dropping ball of prevention and therapy group treatment coronary heart disease generates, significantly increase cytoactive, have obvious antagonism to endothelial injury caused by hydrogen peroxide.
Atherosclerotic lesion is that a kind of protectiveness inflammation-Fibroproliferative to local damage is responded.In Mottling formation process, lipidosis is most important factor.The medicinal dropping ball treatment for the treatment of coronary heart disease can reduce T-CHOL (TC) and low density lipoprotein, LDL (LDL) cholesterol levels, high density lipoprotein increasing (HDL) cholesterol levels.Ma Xiao waits quietly observing the medicinal dropping ball for the treatment of coronary heart disease to the impact of film healing situation in damage with similar method modeling, find that the postoperative NO concentration of medicinal dropping ball group for the treatment of coronary heart disease is apparently higher than matched group, neointimal hyperplasia degree comparatively matched group obviously alleviates, new intima medium vessels smooth muscle cell and fibrous tissue comparatively matched group obviously reduce, therefore think that the medicinal dropping ball for the treatment of coronary heart disease can promote to damage the reparation of inner membrance, reduce neointimal hyperplasia.
The medicinal dropping ball for the treatment of coronary heart disease increases coronary flow, improves lectin from hemolymph hyperlipemia and can cause vascular endothelial injury, come off, platelet adhesion reaction and gathering.The medicinal dropping ball for the treatment of coronary heart disease can significantly increase rat coronary flow but not increase heart rate, contributes to the supply improving heart oxygen and nutrient substance.The medicinal dropping ball for the treatment of coronary heart disease obviously reduces rabbit anteserum TC, triglyceride (TG), LDL, very low density lipoprotein (VLDL) (VLDL) concentration and TC/HDL ratio, obvious raising HDL levels.
The medicinal dropping ball for the treatment of coronary heart disease suppresses platelet adhesion reaction and gathering Endothelial dysfunction, endothelium integrity violations can trigger a series of molecule and biochemical reaction makes blood flow cessation, and blood vessel wall reparation, suppression or antagonism platelet adhesion reaction and gathering prevent thrombotic key link.Medicinal dropping ball D-dimer and the gathering for the treatment of coronary heart disease play a role from multiple location, stage construction and Mutiple Targets.
The medicinal dropping ball for the treatment of coronary heart disease all has obvious inhibitory action to adenosine diphosphate (ADP) (ADP), thrombin and collagen-induced rat platelet aggregation, and in dose-dependence.The medicinal dropping ball for the treatment of coronary heart disease can suppress high fat to feed dog platelet overactivity.Specificity molecular marker when plasma A granule membrane protein140 (GMP-140) is platelet activation.Before treatment, treatment group and matched group GMP-140 level are apparently higher than Healthy People group, after the medicinal dropping ball associating aspirin for treatment for the treatment of coronary heart disease, the improvement for the treatment of group angina pectoris symptom, electrocardiogram ischemia, Plasma C reflect pro tein level comparatively matched group (singly taking aspirin) significantly reduce, with Healthy People group without significant difference.To aspirin resistance person, the medicinal dropping ball of add-on coronary heart disease can obviously improve aspirin resistance state, and reduce platelet aggregation rate, total effective rate is 85%, and mean reduction is 51.57%.
Because the medicinal dropping ball for the treatment of coronary heart disease has above-mentioned multiple target effect, it is to all kinds coronary heart disease, comprise stable or unstable angina pectoris, myocardial infarction, heart failure, silent ischemia and intervention perioperative treatment etc. all have remarkable result.
Following experimental data is for illustration of effect of the present invention: experimental drug is the medicine of the embodiment of the present invention 1.
The comparison of medicinal dropping ball in angina pectoris treatment effect of coronary heart disease treated by table 1
| Group | n | Effective | Effectively | Invalid | Increase the weight of | Total effective rate/% |
| Treatment group | 51 | 19 | 30 | 2 | 0 | 96.1① |
| Matched group | 51 | 7 | 27 | 16 | 1 | 66.6 |
Note: 1. compare with matched group, analyzes through Radit, U=3.039, P < 0.01.
The comparison of medicinal dropping ball in ECG curative effect of coronary heart disease treated by table 2
| Group | n | Effective | Effectively | Invalid | Increase the weight of | Total effective rate/% |
| Treatment group | 51 | 11 | 21 | 19 | 0 | 64.7① |
| Matched group | 51 | 2 | 19 | 28 | 2 | 41.2 |
Note: 1. compare with matched group, analyzes through Radit, U=2.685, P < 0.01.
Medicinal dropping ball treatment front and back hemorheology index change (x ± s) of coronary heart disease treated by table 3
The medicinal dropping ball medication left ventricular contractile function that coronary heart disease treated by table 4 compares (x ± s)
Note: 1. compare before and after medication, P > 0.05; 2. compare before and after medication, P < 0.05.
The pure TCM Dripping Pills of efficient, quick-acting, the multiple-effect that the present invention adopts modern pharmacy technology to develop, prevent and treat coronary heart disease determined curative effect, and can microcirculation be improved, to Diabetic microvascular complication, comprise diabetic renal papillary necrosis and diabetic nephropathy all has good preventive and therapeutic effect.
The invention has the advantages that: this process route can realize industrialization, stable and controllable for quality.Related tests shows, the present invention is higher than prior art curative effect, and product purity is high, good absorbing, steady quality, and purposes is novel, and preparation method technique is simple simultaneously, easy to operate, with low cost, is applicable to suitability for industrialized production.
Detailed description of the invention
Illustrate the present invention with embodiment below, embodiment is for the ease of understanding the present invention, and the claim do not limited the present invention in any way and core content.
Embodiment 1
The preparation of the medicine for the treatment of coronary heart disease, each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 82.87%, Radix Notoginseng 16.21%, Borneolum Syntheticum 0.92%;
Step 1, Radix Salviae Miltiorrhizae adds 5 times amount 95% ethanol, reflux, extract, 2 hours, filters, medicinal residues 3 times amount 95% ethanol, reflux, extract, 1 hour, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 0.4-0.5 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I Tanshinone I I A extract; AB-8 macroporous resin on filtrate, 70% ethanol elution, eluent discards, and continues to use 95% ethanol elution, collect eluent, be concentrated into alcohol content 80%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II Tanshinone I I A extract, and two parts merge, and obtain tanshinone ⅡA extract
Step 2, gets step 1 alcohol extraction medicinal residues, adds 3 times amount 20% alcohol reflux 1hr, filter, medicinal residues add 4 times amount 50% alcohol reflux 1hr, filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 1.8-2.0, cold preservation leaves standstill more than 12hr, filter, upper AB-8 macroporous resin, first wash with water, eluent discards; Wash with 15% ethanol, eluent discards again; Finally wash with 50% ethanol, collect 50% ethanol washing liquid, less than 60 DEG C concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 8 times amount 70% alcohol reflux 2hr, and remaining medicinal residues add 6 times amount 70% alcohol reflux 1hr again, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 2 times medical material amount, upper AB-8 macroporous resin, first wash with water, eluent discards, then uses 50% ethanol elution, collect 50% ethanol elution, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, the medicinal residues of salvianolic acid B after the ethanol extraction of step 2, the aqueous alkali that first time adds 8 times amount PH7-8 decocts 2 hours, and second time adds 8 times amount soak by water 1 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 60%-70%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 70%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone ⅡA extract obtained after said extracted, salvianolic acid B extract, Radix Notoginseng extract is suspended in the pre-PEG-6000 melted successively; Radix Salviae Miltiorrhizae extractum adds water mix homogeneously; Said two devices mix homogeneously; Add Borneolum Syntheticum again, mixing; Material temperature is 60-100 DEG C; The temperature of liquid paraffin is 5-10 DEG C, makes drop pill.
Embodiment 2 treats the preparation of the medicine of coronary heart disease, and each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 19.8%, Radix Notoginseng 78.2%, Borneolum Syntheticum 2%;
Step 1, Radix Salviae Miltiorrhizae adds 2 times amount 95% ethanol, reflux, extract, 1 hour, filters, medicinal residues 20 times amount 95% ethanol, reflux, extract, 1 hour, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 0.4-0.6 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I Tanshinone I I A extract; AB-8 macroporous resin on filtrate, 70% ethanol elution, eluent discards, and continues to use 95% ethanol elution, collect eluent, be concentrated into alcohol content 80%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II Tanshinone I I A extract, and two parts merge, and obtain tanshinone ⅡA extract
Step 2, gets step 1 alcohol extraction medicinal residues, adds 3 times amount 20% alcohol reflux 1hr, filter, medicinal residues add 4 times amount 50% alcohol reflux 1hr, filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 1.8-2.0, cold preservation leaves standstill more than 12hr, filter, upper AB-8 macroporous resin, first wash with water, eluent discards; Wash with 15% ethanol, eluent discards again; Finally wash with 50% ethanol, collect 50% ethanol washing liquid, less than 60 DEG C concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 8 times amount 70% alcohol reflux 1hr, and remaining medicinal residues add again, 6 times amount 70% alcohol reflux 1.5hr, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 2 times medical material amount, upper AB-8 macroporous resin, first washes with water, eluent discards, use 50% ethanol elution again, collect 50% ethanol elution, concentrating under reduced pressure, drying, obtains Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, the aqueous alkali that first time adds 2 times amount PH7-8 decocts 1 hour, and second time adds 2 times amount soak by water 0.5 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 60%-70%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 70%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone ⅡA extract obtained after said extracted, salvianolic acid B extract, Radix Notoginseng extract is suspended in the pre-PEG-6000 melted successively; Radix Salviae Miltiorrhizae extractum adds water mix homogeneously; Said two devices mix homogeneously; Add Borneolum Syntheticum again, mixing; Material temperature is 60-100 DEG C; The temperature of liquid paraffin is 5-10 DEG C, makes drop pill.
Embodiment 3 treats the preparation of the medicine of coronary heart disease, and each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 97%, Radix Notoginseng 2%, Borneolum Syntheticum 1%,
Step 1, Radix Salviae Miltiorrhizae adds 2 times amount 95% ethanol, reflux, extract, 1 hour, filters, medicinal residues 20 times amount 95% ethanol, reflux, extract, 10 hours, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 0.2 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I tanshinone ⅡA extract; AB-8 macroporous resin on filtrate, 50% ethanol elution, eluent discards, and continues to use 85% ethanol elution, collect eluent, be concentrated into alcohol content 65%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II Tanshinone I I A extract, and two parts merge, and obtain tanshinone ⅡA extract;
Step 2, gets step 1 alcohol extraction medicinal residues, adds 8 times amount 60% alcohol reflux 4hr, filter, medicinal residues add 4 times amount 50% alcohol reflux 1hr, filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 1.8-2.0, cold preservation leaves standstill more than 12hr, filter, upper AB-8 macroporous resin, first wash with water, eluent discards; Wash with 15% ethanol, eluent discards again; Finally wash with 50% ethanol, collect 50% ethanol washing liquid, less than 60 DEG C concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 6 times amount 70% alcohol reflux 2hr, and remaining medicinal residues add 7 times amount 70% alcohol reflux 3hr again, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 1 times medical material amount, upper AB-8 macroporous resin, first wash with water, eluent discards, then uses 50% ethanol elution, collect 50% ethanol elution, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, the aqueous alkali that first time adds 6 times amount PH7-8 decocts 3 hours, and second time adds 6 times amount soak by water 2 hours, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 60%-70%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 70%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone ⅡA extract obtained after said extracted, salvianolic acid B extract, Radix Notoginseng extract is suspended in the pre-PEG-6000 melted successively; Radix Salviae Miltiorrhizae extractum adds water mix homogeneously; Said two devices mix homogeneously; Add Borneolum Syntheticum again, mixing; Material temperature is 60-100 DEG C; The temperature of liquid paraffin is 5-10 DEG C, makes drop pill.
Embodiment 4 treats the preparation of the medicine of coronary heart disease, and each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 95%, Radix Notoginseng 2%, Borneolum Syntheticum 3%,
Step 1, Radix Salviae Miltiorrhizae adds 15 times amount 95% ethanol, reflux, extract, 3 hours, filters, medicinal residues 15 times amount 95% ethanol, reflux, extract, 10 hours, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 5 times of medical material amounts, leave standstill, and filter; Precipitation is dry, obtains Part I Tanshinone I I A extract; S-8 macroporous resin on filtrate, 85% ethanol elution, eluent discards, and continues to use 100% ethanol elution, collect eluent, be concentrated into alcohol content 85%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone ⅡA extract, and two parts merge, and obtain tanshinone ⅡA extract;
Step 2, gets step 1 alcohol extraction medicinal residues, adds 4 times amount 50% ethanol ultrasonic extraction 2hr, filter, medicinal residues add 4 times amount 50% ethanol ultrasonic extraction 1hr, filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 1.8-2.0, cold preservation leaves standstill more than 12hr, filter, upper AB-8 macroporous resin, first wash with water, eluent discards; Wash with 15% ethanol, eluent discards again; Finally wash with 50% ethanol, collect 50% ethanol washing liquid, less than 60 DEG C concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 8 times amount 60% alcohol reflux 1hr, and remaining medicinal residues add 6 times amount 80% alcohol reflux 3hr again, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 3 times medical material amount, upper AB-8 macroporous resin, first wash with water, eluent discards, then uses 50% ethanol elution, collect 50% ethanol elution, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, Radix Salviae Miltiorrhizae decoction dregs after the ethanol extraction of step 2, the aqueous alkali that first time adds 8 times amount PH7-8 decocts 2 hours, and second time adds 6 times amount soak by water 1 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 60%-70%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 70%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone ⅡA extract obtained after said extracted, salvianolic acid B extract, Radix Notoginseng extract, Radix Salviae Miltiorrhizae extractum, Borneolum Syntheticum, add and can press starch in right amount, mixing; Make tablet.
Embodiment 5 treats the preparation of the medicine of coronary heart disease, and each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 19.8%, Radix Notoginseng 80%, Borneolum Syntheticum 0.2%,
Step 1, Radix Salviae Miltiorrhizae adds 2 times amount 95% ethanol, reflux, extract, 3 hours, filters, medicinal residues 15 times amount 95% ethanol, reflux, extract, 2 hours, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 1 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I tanshinone ⅡA extract; D101 macroporous resin on filtrate, 70% ethanol elution, eluent discards, and continues to use 95% ethanol elution, collect eluent, be concentrated into alcohol content 80%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone ⅡA extract, and two parts merge, and obtain tanshinone ⅡA extract;
Step 2, gets step 1 alcohol extraction medicinal residues, adds 4 times amount 50% ethanol dynamic countercurrent extraction 2hr, filter, medicinal residues add 4 times amount 50% ethanol dynamic countercurrent extraction 1hr, filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 1.8-2.0, cold preservation leaves standstill more than 12hr, filter, upper AB-8 macroporous resin, first wash with water, eluent discards; Wash with 15% ethanol, eluent discards again; Finally wash with 50% ethanol, collect 50% ethanol washing liquid, less than 60 DEG C concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 2 times amount 70% alcohol reflux 2hr, and remaining medicinal residues add 20 times amount 70% alcohol reflux 1hr again, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 2 times medical material amount, upper AB-8 macroporous resin, first wash with water, eluent discards, then uses 50% ethanol elution, collect 50% ethanol elution, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, the aqueous alkali that first time adds 8 times amount PH7-8 decocts 2 hours, and second time adds 6 times amount soak by water 1 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 60%-70%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 70%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the Tanshinone I I A extract obtained after said extracted, salvianolic acid B extract, Radix Notoginseng extract is suspended in the pre-PEG-6000 melted successively; Radix Salviae Miltiorrhizae extractum adds water mix homogeneously; Said two devices mix homogeneously; Add Borneolum Syntheticum again, mixing; Material temperature is 60-100 DEG C; The temperature of liquid paraffin is 5-10 DEG C, makes drop pill.
Embodiment 6 treats the preparation of the medicine of coronary heart disease, and each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 20.8%, Radix Notoginseng 78.6%, Borneolum Syntheticum 0.6%,
Step 1, Radix Salviae Miltiorrhizae adds 10 times amount 95% ethanol, reflux, extract, 3 hours, filters, medicinal residues 2 times amount 95% ethanol, reflux, extract, 2 hours, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 1 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I tanshinone ⅡA extract; D101 macroporous resin on filtrate, 70% ethanol elution, eluent discards, and continues to use 95% ethanol elution, collect eluent, be concentrated into alcohol content 80%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone ⅡA extract, and two parts merge, and obtain tanshinone ⅡA extract;
Step 2, gets step 1 alcohol extraction medicinal residues, adds 4 times amount 50% alcohol reflux 2hr, filter, medicinal residues add 4 times amount 50% alcohol reflux 1hr, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 1.0-4.0, cold preservation leaves standstill more than 12hr, upper AB-8 macroporous resin, first wash with water, eluent discards; Wash with 15% ethanol, eluent discards again; Finally wash with 50% ethanol, collect 50% ethanol washing liquid, less than 60 DEG C concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 5 times amount 60% alcohol reflux 2hr, and remaining medicinal residues add 18 times amount 60% alcohol reflux 1hr again, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 1 times medical material amount, upper S-8 macroporous resin, first wash with water, eluent discards, then uses 50% methanol-eluted fractions, collect 50% meoh eluate, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, the aqueous alkali that first time adds 8 times amount PH7-8 decocts 2 hours, and second time adds 6 times amount soak by water 1 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 60%-70%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 70%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone ⅡA extract obtained after said extracted, salvianolic acid B extract, Radix Notoginseng extract is suspended in the pre-PEG-6000 melted successively; Radix Salviae Miltiorrhizae extractum adds water mix homogeneously; Said two devices mix homogeneously; Add Borneolum Syntheticum again, mixing; Material temperature is 60-100 DEG C; The temperature of liquid paraffin is 5-10 DEG C, makes drop pill.
Embodiment 7 treats the preparation of the medicine of coronary heart disease, and each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 29.8%, Radix Notoginseng 68.6%, Borneolum Syntheticum 1.6%,
Step 1, Radix Salviae Miltiorrhizae adds 10 times amount 60% ethanol, reflux, extract, 3 hours, filters, medicinal residues 8 times amount 60% ethanol, reflux, extract, 2 hours, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 1 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I Tanshinone I I A extract; D101 macroporous resin on filtrate, 70% ethanol elution, eluent discards, and continues to use 95% ethanol elution, collect eluent, be concentrated into alcohol content 80%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II Tanshinone I I A extract, and two parts merge, and obtain tanshinone ⅡA extract;
Step 2, gets step 1 alcohol extraction medicinal residues, adds 2 times amount 10% ethanol warm macerating and extracts 2hr, filter, medicinal residues add 4 times amount 90% ethanol warm macerating and extract 1hr, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 1.8-2.0, cold preservation leaves standstill more than 12hr, upper AB-8 macroporous resin, first wash with water, eluent discards; Wash with 15% ethanol, eluent discards again; Finally wash with 50% ethanol, collect 50% ethanol washing liquid, less than 60 DEG C concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 5 times amount 60% alcohol reflux 2hr, and remaining medicinal residues add 18 times amount 60% alcohol reflux 1hr again, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 1 times medical material amount, upper D101 macroporous resin, first wash with water, eluent discards, then uses 40% normal propyl alcohol eluting, collect 40% normal propyl alcohol eluent, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, the aqueous alkali that first time adds 8 times amount PH7-8 decocts 2 hours, and second time adds 6 times amount soak by water 1 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 60%-70%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 70%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone ⅡA extract obtained after said extracted, salvianolic acid B extract, Radix Notoginseng extract is suspended in the pre-PEG-6000 melted successively; Radix Salviae Miltiorrhizae extractum adds water mix homogeneously; Said two devices mix homogeneously; Add Borneolum Syntheticum again, mixing; Material temperature is 60-100 DEG C; The temperature of liquid paraffin is 5-10 DEG C, makes drop pill.
Embodiment 8 treats the preparation of the medicine of coronary heart disease, and each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 86.8%, Radix Notoginseng 12.6%, Borneolum Syntheticum 0.6%,
Step 1, Radix Salviae Miltiorrhizae adds 10 times amount 100% ethanol, reflux, extract, 3 hours, filters, medicinal residues 8 times amount 60% ethanol, reflux, extract, 2 hours, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 1 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I tanshinone ⅡA extract; D101 macroporous resin on filtrate, 70% ethanol elution, eluent discards, and continues to use 95% ethanol elution, collect eluent, be concentrated into alcohol content 80%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone ⅡA extract, and two parts merge, and obtain tanshinone ⅡA extract;
Step 2, gets step 1 alcohol extraction medicinal residues, adds 4 times amount 50% ethanol ultrasonic extraction 2hr, filter, medicinal residues add 4 times amount 50% ethanol ultrasonic extraction 1hr, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 2.0-4.0, cold preservation leaves standstill more than 12hr, upper AB-8 macroporous resin, first wash with water, eluent discards; Wash with 15% ethanol, eluent discards again; Finally wash with 50% ethanol, collect 50% ethanol washing liquid, less than 60 DEG C concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 5 times amount 60% alcohol reflux 2hr, and remaining medicinal residues add 18 times amount 60% alcohol reflux 1hr again, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 1 times medical material amount, upper D101 macroporous resin, first wash with water, eluent discards, then uses 60% isopropyl alcohol alcohol eluting, collect 60% isopropyl alcohol eluent, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, the aqueous alkali that first time adds 8 times amount PH7-8 decocts 2 hours, and second time adds 6 times amount soak by water 1 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 60%-70%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 70%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone ⅡA extract obtained after said extracted, salvianolic acid B extract, Radix Notoginseng extract is suspended in the pre-PEG-6000 melted successively; Radix Salviae Miltiorrhizae extractum adds water mix homogeneously; Said two devices mix homogeneously; Add Borneolum Syntheticum again, mixing; Material temperature is 80-100 DEG C; The temperature of liquid paraffin is 5-10 DEG C, makes drop pill.
Embodiment 9 treats the preparation of the medicine of coronary heart disease, and each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 85.8%, Radix Notoginseng 12.6%, Borneolum Syntheticum 1.6%,
Step 1, Radix Salviae Miltiorrhizae adds 10 times amount 95% ethanol, reflux, extract, 10 hours, filters, medicinal residues 8 times amount 95% ethanol, reflux, extract, 1 hour, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 1 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I Tanshinone I I A extract; D101 macroporous resin on filtrate, 70% ethanol elution, eluent discards, and continues to use 95% ethanol elution, collect eluent, be concentrated into alcohol content 80%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone ⅡA extract, and two parts merge, and obtain tanshinone ⅡA extract;
Step 2, gets step 1 alcohol extraction medicinal residues, adds 4 times amount 50% ethanol ultrasonic extraction 2hr, filter, medicinal residues add 4 times amount 50% ethanol ultrasonic extraction 1hr, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 1.0-2.0, cold preservation leaves standstill more than 12hr, upper S-8 macroporous resin, first wash with water, eluent discards; Wash with 15% ethanol, eluent discards again; Finally wash with 50% ethanol, collect 50% ethanol washing liquid, less than 60 DEG C concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 5 times amount 60% alcohol reflux 2hr, and remaining medicinal residues add 18 times amount 60% alcohol reflux 1hr again, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 1 times medical material amount, upper D101 macroporous resin, first wash with water, eluent discards, then uses 40% ethanol elution, collect 40% ethanol elution, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, the aqueous alkali that first time adds 8 times amount PH7-8 decocts 2 hours, and second time adds 6 times amount soak by water 1 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 60%-70%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 70%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the Tanshinone I I A extract, salvianolic acid B extract, Radix Notoginseng extract, Radix Salviae Miltiorrhizae extractum, the Borneolum Syntheticum that obtain after said extracted, add appropriate amount of starch, and mixing, tabletting, makes tablet.
Embodiment 10 treats the preparation of the medicine of coronary heart disease, and each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 74.8%, Radix Notoginseng 23.6%, Borneolum Syntheticum 1.6%,
Step 1, Radix Salviae Miltiorrhizae adds 10 times amount 95% ethanol, reflux, extract, 3 hours, filters, medicinal residues 8 times amount 95% ethanol, reflux, extract, 2 hours, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 1 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I Tanshinone I I A extract; D101 macroporous resin on filtrate, 60% ethanol elution, eluent discards, and continues to use 85% ethanol elution, collect eluent, be concentrated into alcohol content 65%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II Tanshinone I I A extract, and two parts merge, and obtain tanshinone ⅡA extract;
Step 2, gets step 1 alcohol extraction medicinal residues, adds 4 times amount 50% ethanol dynamic countercurrent extraction 2hr, filter, medicinal residues add 4 times amount 50% ethanol dynamic countercurrent extraction 1hr, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 2.0-4.0, cold preservation leaves standstill more than 12hr, upper AB-8 macroporous resin, first wash with water, eluent discards; Wash with 15% ethanol, eluent discards again; Finally wash with 50% ethanol, collect 50% ethanol washing liquid, less than 60 DEG C concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 5 times amount 60% alcohol reflux 2hr, and remaining medicinal residues add 18 times amount 60% alcohol reflux 1hr again, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 1 times medical material amount, upper D101 macroporous resin, first wash with water, eluent discards, then uses 40% ethanol elution, collect 40% ethanol elution, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, the aqueous alkali that first time adds 8 times amount PH7-8 decocts 2 hours, and second time adds 6 times amount soak by water 1 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 60%-70%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 70%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone ⅡA extract obtained after said extracted, salvianolic acid B extract, Radix Notoginseng extract is suspended in the pre-PEG-6000 melted successively; Radix Salviae Miltiorrhizae extractum adds water mix homogeneously; Said two devices mix homogeneously; Add Borneolum Syntheticum again, mixing; Material temperature is 80-100 DEG C; The temperature of liquid paraffin is 5-10 DEG C, makes drop pill.
Embodiment 11 treats the preparation of the medicine of coronary heart disease, and each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 58.8%, Radix Notoginseng 40.6%, Borneolum Syntheticum 0.6%,
Step 1, Radix Salviae Miltiorrhizae adds 4 times amount 95% ethanol, reflux, extract, 1 hour, filters, medicinal residues 5 times amount 95% ethanol, reflux, extract, 2 hours, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 0.2 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I tanshinone ⅡA extract; D101 macroporous resin on filtrate, 60% ethanol elution, eluent discards, and continues to use 85% ethanol elution, collect eluent, be concentrated into alcohol content 65%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone ⅡA extract, and two parts merge, and obtain tanshinone ⅡA extract;
Step 2, gets step 1 alcohol extraction medicinal residues, adds 4 times amount 50% methanol dynamic countercurrent extraction 2hr, filter, medicinal residues add 4 times amount 50% methanol dynamic countercurrent extraction 1hr, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 2.0-3.0, cold preservation leaves standstill more than 12hr, upper AB-8 macroporous resin, first wash with water, eluent discards; Wash with 10% ethanol, eluent discards again; Finally wash with 50% ethanol, collect 50% ethanol washing liquid, less than 60 DEG C concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 6 times amount 50% alcohol reflux 2hr, and remaining medicinal residues add 18 times amount 50% alcohol reflux 1hr again, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 1 times medical material amount, upper D101 macroporous resin, first wash with water, eluent discards, then uses 30% ethanol elution, collect 30% ethanol elution, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, the aqueous alkali that first time adds 2 times amount PH7-8 decocts 2 hours, and second time adds 2 times amount soak by water 1 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 60%-70%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 70%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the Tanshinone I I A extract obtained after said extracted, salvianolic acid B extract, Radix Notoginseng extract is suspended in the pre-PEG-6000 melted successively; Radix Salviae Miltiorrhizae extractum adds water mix homogeneously; Said two devices mix homogeneously; Add Borneolum Syntheticum again, mixing; Material temperature is 80-100 DEG C; The temperature of liquid paraffin is 5-10 DEG C, makes drop pill.
Embodiment 12 treats the preparation of the medicine of coronary heart disease, and each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 28%, Radix Notoginseng 70%, Borneolum Syntheticum 2%;
Step 1, Radix Salviae Miltiorrhizae adds 10 times amount 65% methanol, reflux, extract, 1 hour, filters, medicinal residues 5 times amount 95% methanol, reflux, extract, 5 hours, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 0.8 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I tanshinone ⅡA extract; D101 macroporous resin on filtrate, 85% ethanol elution, eluent discards, and continues to use 100% ethanol elution, collect eluent, be concentrated into alcohol content 85%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone ⅡA extract, and two parts merge, and obtain tanshinone ⅡA extract;
Step 2, gets step 1 alcohol extraction medicinal residues, adds 4 times amount 50% methanol dynamic countercurrent extraction 2hr, filter, medicinal residues add 4 times amount 50% methanol dynamic countercurrent extraction 1hr, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 2.0-3.0, cold preservation leaves standstill more than 12hr, upper AB-8 macroporous resin, first wash with water, eluent discards; Wash with 10% ethanol, eluent discards again; Finally wash with 45% ethanol, collect 45% ethanol washing liquid, less than 60 DEG C concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 6 times amount 50% methanol eddies and extracts 2hr, and remaining medicinal residues add 18 times amount 50% methanol eddies again and extract 1hr, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 1 times medical material amount, upper D101 macroporous resin, first wash with water, eluent discards, then uses 60% ethanol elution, collect 60% ethanol elution, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, the aqueous alkali that first time adds 12 times amount PH7-8 decocts 2 hours, and second time adds 12 times amount soak by water 1 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 60%-70%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 70%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone ⅡA extract obtained after said extracted, salvianolic acid B extract, Radix Notoginseng extract, Radix Salviae Miltiorrhizae extractum, Borneolum Syntheticum, add appropriate dextrin, mucialga of arabic gummy mixing, granulate; Incapsulate, make capsule.
Embodiment 13 treats the preparation of the medicine of coronary heart disease, and each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 85%, Radix Notoginseng 12%, Borneolum Syntheticum 3%;
Step 1, Radix Salviae Miltiorrhizae adds 5 times amount 95% normal propyl alcohols, reflux, extract, 2 hours, filters, medicinal residues 3 times amount 95% normal propyl alcohols, reflux, extract, 1 hour, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 0.4-0.5 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I Tanshinone I I A extract; AB-8 macroporous resin on filtrate, 70% ethanol elution, eluent discards, and continues to use 95% ethanol elution, collect eluent, be concentrated into alcohol content 80%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone ⅡA extract, and two parts merge, and obtain tanshinone ⅡA extract
Step 2, gets step 1 alcohol extraction medicinal residues, adds 4 times amount 50% n-butyl alcohol dynamic countercurrent extraction 2hr, filter, medicinal residues add 4 times amount 50% n-butyl alcohol dynamic countercurrent extraction 1hr, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 2.0-3.0, cold preservation leaves standstill more than 12hr, upper AB-8 macroporous resin, first wash with water, eluent discards; Wash with 13% ethanol, eluent discards again; Finally wash with 65% ethanol, collect 65% ethanol washing liquid, less than 60 DEG C concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 5 times amount 60% normal propyl alcohol reflux, extract, 2hr, and remaining medicinal residues add 10 times amount 60% normal propyl alcohol reflux, extract, 1hr again, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 1 times medical material amount, upper D101 macroporous resin, first wash with water, eluent discards, then uses 40% ethanol elution, collect 40% ethanol elution, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, the aqueous alkali that first time adds 7 times amount PH7-8 decocts 2 hours, and second time adds 6 times amount soak by water 1 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 50%-80%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 50%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the Tanshinone I I A extract, salvianolic acid B extract, Radix Notoginseng extract, Radix Salviae Miltiorrhizae extractum, the Borneolum Syntheticum that obtain after said extracted, add microcrystalline Cellulose, sodium carboxymethyl cellulose, gelatine size mixing; Granulate, make granule.
Embodiment 14 treats the preparation of the medicine of coronary heart disease, and each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 50%, Radix Notoginseng 48%, Borneolum Syntheticum 2%;
Step 1, Radix Salviae Miltiorrhizae adds 5 times amount 95% isopropyl alcohols, reflux, extract, 2 hours, filters, medicinal residues 3 times amount 95% isopropyl alcohols, reflux, extract, 1 hour, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 0.4-0.5 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I Tanshinone I I A extract; AB-8 macroporous resin on filtrate, 70% ethanol elution, eluent discards, and continues to use 95% ethanol elution, collect eluent, be concentrated into alcohol content 80%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone ⅡA extract, and two parts merge, and obtain tanshinone ⅡA extract
Step 2, gets step 1 alcohol extraction medicinal residues, adds 4 times amount 50% methanol dynamic countercurrent extraction 2hr, filter, medicinal residues add 4 times amount 50% methanol dynamic countercurrent extraction 1hr, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 2.0-3.0, cold preservation leaves standstill more than 12hr, upper D101 macroporous resin, first wash with water, eluent discards; Wash with 10% ethanol, eluent discards again; Finally wash with 70% ethanol, collect 70% ethanol washing liquid, less than 60 DEG C concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 6 times amount 50% isopropyl alcohol reflux, extract, 2hr, and remaining medicinal residues add 18 times amount 50% isopropyl alcohol reflux, extract, 1hr again, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 1 times medical material amount, upper D101 macroporous resin, first wash with water, eluent discards, then uses 60% ethanol elution, collect 60% ethanol elution, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, the aqueous alkali that first time adds 7 times amount PH7-10 decocts 2 hours, and second time adds 6 times amount soak by water 1 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 50%-80%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 90%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the Tanshinone I I A extract, salvianolic acid B extract, Radix Notoginseng extract, Radix Salviae Miltiorrhizae extractum, the Borneolum Syntheticum that obtain after said extracted, add appropriate amount of starch, Mel mix homogeneously; Make pill.
Embodiment 15 treats the preparation of the medicine of coronary heart disease, and each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 90%, Radix Notoginseng 8%, Borneolum Syntheticum 2%;
Step 1, Radix Salviae Miltiorrhizae adds 5 times amount 95% n-butyl alcohol, reflux, extract, 2 hours, filters, medicinal residues 3 times amount 95% n-butyl alcohol, reflux, extract, 1 hour, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 0.4-0.5 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I Tanshinone I I A extract; AB-8 macroporous resin on filtrate, 70% ethanol elution, eluent discards, and continues to use 95% ethanol elution, collect eluent, be concentrated into alcohol content 80%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone ⅡA extract, and two parts merge, and obtain tanshinone ⅡA extract
Step 2, gets step 1 alcohol extraction medicinal residues, adds 4 times amount 50% isobutanol dynamic countercurrent extraction 2hr, filter, medicinal residues add 4 times amount 50% isobutanol dynamic countercurrent extraction 1hr, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 2.0-3.0, cold preservation leaves standstill more than 12hr, upper AB-8 macroporous resin, first wash with water, eluent discards; Wash with 13% ethanol, eluent discards again; Finally wash with 65% ethanol, collect 65% ethanol washing liquid, less than 60 DEG C concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 6 times amount 50% n-butyl alcohol reflux, extract, 2hr, and remaining medicinal residues add 7 times amount 50% n-butyl alcohol reflux, extract, 1hr again, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 1 times medical material amount, upper D101 macroporous resin, first wash with water, eluent discards, then uses 60% ethanol elution, collect 60% ethanol elution, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, the aqueous alkali that first time adds 7 times amount PH7-10 decocts 2 hours, and second time adds 6 times amount soak by water 1 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 50%-80%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 90%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the Tanshinone I I A extract, salvianolic acid B extract, Radix Notoginseng extract, Radix Salviae Miltiorrhizae extractum, the Borneolum Syntheticum that obtain after said extracted, add appropriate mannitol, magnesium oxide, calcium carbonate mixing; Tabletting, makes tablet.
Embodiment 16 treats the preparation of the medicine of coronary heart disease, and each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 82%, Radix Notoginseng 17%, Borneolum Syntheticum 1%;
Step 1, Radix Salviae Miltiorrhizae adds 5 times amount 95% isobutanol, reflux, extract, 2 hours, filters, medicinal residues 3 times amount 95% isobutanol, reflux, extract, 1 hour, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 0.4-0.5 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I Tanshinone I I A extract; AB-8 macroporous resin on filtrate, 70% ethanol elution, eluent discards, and continues to use 95% ethanol elution, collect eluent, be concentrated into alcohol content 80%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone ⅡA extract, and two parts merge, and obtain tanshinone ⅡA extract
Step 2, gets step 1 alcohol extraction medicinal residues, adds 4 times amount 50% n-butyl alcohol dynamic countercurrent extraction 2hr, filter, medicinal residues add 4 times amount 50% n-butyl alcohol dynamic countercurrent extraction 1hr, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 2.0-3.0, cold preservation leaves standstill more than 12hr, upper AB-8 macroporous resin, first wash with water, eluent discards; Wash with 13% ethanol, eluent discards again; Finally wash with 70% ethanol, collect 70% ethanol washing liquid, less than 60 DEG C concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 6 times amount 50% isobutanol reflux, extract, 1hr, and remaining medicinal residues add 10 times amount 50% isobutanol reflux, extract, 1hr again, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 2 times medical material amount, upper D101 macroporous resin, first wash with water, eluent discards, then uses 60% ethanol elution, collect 60% ethanol elution, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, the aqueous alkali that first time adds 6 times amount PH7-10 decocts 2 hours, and second time adds 9 times amount soak by water 2 hours, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 50%-80%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 90%, obtain Salvia miltiorrhiza and Panax notoginseng extractum;
Step 5, the tanshinone ⅡA extract obtained after said extracted, salvianolic acid B extract, Radix Notoginseng extract, Radix Salviae Miltiorrhizae extractum, Borneolum Syntheticum, get appropriate vegetable oil, makes soft capsule according to soft capsule preparation method.
Embodiment 17 treats the preparation of the medicine of coronary heart disease, and each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 82.87%, Radix Notoginseng 16.21%, Borneolum Syntheticum 0.92%;
Step 1, Radix Salviae Miltiorrhizae adds 5 times amount 95% ethanol, reflux, extract, 2 hours, filters, medicinal residues 3 times amount 95% ethanol, reflux, extract, 1 hour, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 2 times of medical material amounts, leave standstill, and filter; Precipitation is dry, obtains Part I tanshinone ⅡA extract; S-8 macroporous resin on filtrate, 70% ethanol elution, eluent discards, and continues to use 95% ethanol elution, collect eluent, be concentrated into alcohol content 80%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II Tanshinone I I A extract, and two parts merge, and obtain tanshinone ⅡA extract
Step 2, gets step 1 Radix Salviae Miltiorrhizae alcohol extraction medicinal residues and adds 2 times amount 10% isopropyl alcohol warm macerating and extract 0.5 hour, filters, remaining medicinal residues add 2 times amount alcohol warm macerating and extract 10 hours, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to liquid PH value 1-4, leave standstill, filter, filtrate crosses macroporous resin D101, washes with water successively, 10% ethanol elution, 60% ethanol elution, collects 60% ethanol elution, concentrated, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 6 times amount 50% alcohol reflux 2hr, and remaining medicinal residues add 18 times amount 50% alcohol reflux 1hr again, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 1 times medical material amount, upper D101 macroporous resin, first wash with water, eluent discards, then uses 60% ethanol elution, collect 60% ethanol elution, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 5, first time adds 8 times amount PH7-8, and 0.2% sodium bicarbonate solution decocts 2 hours, second time adds 8 times amount soak by water 1 hour, obtain extracting solution, extracting solution concentrates, and adds ethanol to medicinal liquid alcohol content 60%-70%, leave standstill more than 12 hours, separation of supernatant, reclaims ethanol, receives cream to pol 70%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone ⅡA extract obtained after said extracted, salvianolic acid B extract, Radix Notoginseng extract is suspended in the pre-PEG-6000 melted successively; Radix Salviae Miltiorrhizae extractum adds water mix homogeneously; Said two devices mix homogeneously; Add Borneolum Syntheticum again, mixing; Material temperature is 80 DEG C; The temperature of liquid paraffin is 8 DEG C, makes drop pill.
Embodiment 18 treats the preparation of the medicine of coronary heart disease, and each component consists of in the weight percent of crude drug effective ingredient: Radix Salviae Miltiorrhizae 82.87%, Radix Notoginseng 16.21%, Borneolum Syntheticum 0.92%;
Step 1, Radix Salviae Miltiorrhizae adds 5 times amount 95% ethanol, reflux, extract, 2 hours, filters, medicinal residues 3 times amount 95% ethanol, reflux, extract, 1 hour, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 3 times of medical material amounts, leave standstill, and filter; Precipitation is dry, obtains Part I Tanshinone I I A extract; AB-8 macroporous resin on filtrate, 70% ethanol elution, eluent discards, and continues to use 95% ethanol elution, collect eluent, be concentrated into alcohol content 80%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone ⅡA extract, and two parts merge, and obtain tanshinone ⅡA extract
Step 2, gets step 1 Radix Salviae Miltiorrhizae alcohol extraction medicinal residues and adds 20 times amount 10% normal propyl alcohol reflux, extract, 10 hours, filters, remaining medicinal residues add 20 times amount alcohol extraction 1.5 hours, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to liquid PH value 1-4, leave standstill, filter, filtrate crosses macroporous resin S-8, washes with water successively, 10% ethanol elution, 60% ethanol elution, collects 60% ethanol elution, concentrated, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 6 times amount 50% alcohol reflux 2hr, and remaining medicinal residues add 18 times amount 50% alcohol reflux 1hr again, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 1 times medical material amount, upper AB-8 macroporous resin, first wash with water, eluent discards, then uses 60% ethanol elution, collect 60% ethanol elution, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, salvianolic acid B medicinal residues after the ethanol extraction of step 2, first time adds 8 times amount PH7-8, and 0.6% sodium bicarbonate solution decocts 2 hours, second time adds 8 times amount soak by water 1 hour, obtain extracting solution, extracting solution concentrates, and adds ethanol to medicinal liquid alcohol content 60%-70%, leave standstill more than 12 hours, separation of supernatant, reclaims ethanol, receives cream to pol 70%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone ⅡA extract obtained after said extracted, salvianolic acid B extract, Radix Notoginseng extract, Radix Salviae Miltiorrhizae extractum, Borneolum Syntheticum, get suitable amount of sucrose powder, essence add appropriate water, make oral liquid.
Claims (7)
1. treat a medicine for coronary heart disease, described medicine is prepared from by the crude drug of following percentage by weight, Radix Salviae Miltiorrhizae 19.8%-97%, Radix Notoginseng 2%-80%, Borneolum Syntheticum 0.2%-3%, described preparation first crude drug is prepared into active constituents of medicine through following steps, be prepared into medicine further again
Step 1, Radix Salviae Miltiorrhizae adds the alcohol extraction 1-10 hour of 2-20 times amount 60% ~ 100%, filters, medicinal residues 2-20 times amount 60% ~ 100% alcohol extraction 1-10 hour, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 0.2-5 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I tanshinone IIA extract; Macroporous resin on filtrate, 50-85% ethanol elution, eluent discards, then uses 85-100% ethanol elution, collect eluent, be concentrated into alcohol content 65-85%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone IIA extract, and two parts merge, and obtain tanshinone IIA extract;
Step 2, gets step 1 Radix Salviae Miltiorrhizae alcohol extraction medicinal residues and adds 2-20 times amount 10-60% alcohol extraction 0.5-10 hour, filters, remaining medicinal residues add 2-20 times amount 50-100% methanol or ethanol extraction 0.5-10 hour, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 1-4, leave standstill, filter, filtrate crosses macroporous resin, washes with water successively, 5-20% ethanol elution, 40-90% ethanol elution, collects 40-90% ethanol elution, concentrated, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds alcohol reflux 1-2 time of 2-20 times of 50-100%, each extraction time 0.5-10 hour, extracting liquid filtering, filtrate is concentrated into without alcohol taste, adds the distilled water of 1-3 times of medical material amount, upper macroporous resin, first wash with water, eluent discards, then uses 30-60% methanol or ethanol elution, collect alcohol eluen, concentrated, dry, obtain Radix Notoginseng extract;
Step 4, the medicinal residues after step 2 alcohol extraction, add the aqueous alkali of 2-12 times of pH value 7-10, extract 1-3 time, add 2-12 times of water again, extract 1-3 time, filter, filtrate concentrates, add ethanol to medicinal liquid alcohol content 50-80%, leave standstill, separation of supernatant, reclaim ethanol, receive cream to pol 50%-90% or concentrated, dry, pulverizing, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, by tanshinone IIA extract obtained above, salvianolic acid B extract, Radix Notoginseng extract, Radix Salviae Miltiorrhizae extractum mixes with adjuvant with Borneolum Syntheticum, adds any one or more than one adjuvants, adjuvant addition is 1-6 times of active component, make drop pill, described adjuvant is selected from fat-soluble substrate and water-soluble base, and wherein fat-soluble substrate is selected from: stearic acid, glyceryl monostearate, insect wax, Cera Flava, paraffin, hydrogenated vegetable oil, semi-synthetic fatty acid ester; Water-soluble base is selected from Polyethylene Glycol, polyoxyethylene monostearate, poloxamer, sodium stearate, glycerin gelatine; Xylitol and composites of starch, erythritol;
Wherein described in step 1 and 2, alcohol is selected from: methanol, ethanol, and described extracting mode is selected from: the extraction of reflux, extract, warm macerating, merceration extraction, seepage pressure effects, supersound extraction, dynamic countercurrent extraction or microwave extraction,
Wherein, macroporous resin described in step 1 and step 3 is selected from: polar resin S-8, low pole Resin A B-8 or non-polar resin D101;
Wherein, described in step 2, macroporous resin is selected from: polar resin S-8, low pole Resin A B-8, non-polar resin D101.
2. the medicine of the treatment coronary heart disease of claim 1, is drop pill, it is characterized in that, preparation process is:
Step 1, Radix Salviae Miltiorrhizae adds the alcohol extraction 1-8 hour of 2-15 times amount 60% ~ 100%, filters, the medicinal residues alcohol extraction 1-8 hour of 2-15 times amount 60% ~ 100%, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 0.2-3 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I tanshinone IIA extract; Macroporous resin on filtrate, 50-85% ethanol elution, eluent discards, then uses 85-100% ethanol elution, collect eluent, be concentrated into alcohol content 65-85%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone IIA extract, and two parts merge, and obtain tanshinone IIA extract;
Step 2, gets step 1 Radix Salviae Miltiorrhizae alcohol extraction medicinal residues and adds 2-15 times amount 10-60% alcohol extraction 1-8 hour, filters, remaining medicinal residues add 2-15 times amount 50-90% methanol or ethanol extraction 1-8 hour, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 1-3, leave standstill, filter, filtrate crosses macroporous resin, washes with water successively, 5-20% ethanol elution, finally uses 40-90% ethanol elution, collects 40-90% ethanol elution, concentrated, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds alcohol reflux 1-2 time of 2-10 times of 60-80%, each extraction time 0.5-3 hour, extracting liquid filtering, filtrate is concentrated into without alcohol taste, adds the distilled water of 1-3 times of medical material amount, upper macroporous resin, first wash with water, eluent discards, then uses 30-60% ethanol elution, collect alcohol eluen, concentrated, dry, obtain Radix Notoginseng extract;
Step 4, medicinal residues after step 2 alcohol extraction, the aqueous alkali that first time adds 2-12 times amount pH7-8 decocts 1-3 hour, and second time adds 2-12 times amount soak by water 0.5-2 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 50%-80%, leave standstill 12-36 hour, separation of supernatant, reclaim ethanol, receive cream to pol 55%-80%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone IIA extract of step 1, salvianolic acid B extract, Radix Notoginseng extract is suspended in the pre-PEG-6000 melted successively; Radix Salviae Miltiorrhizae extractum adds water mix homogeneously; Said two devices mix homogeneously; Add Borneolum Syntheticum again, mixing; Material temperature is 60-100 DEG C; The temperature of liquid paraffin is 0-10 DEG C, makes drop pill;
Wherein described in step 1 and 2, alcohol is selected from: methanol, ethanol, and described extracting mode is selected from: the extraction of reflux, extract, warm macerating, merceration extraction, seepage pressure effects, supersound extraction, dynamic countercurrent extraction or microwave extraction;
Wherein, described in step 1 to step 3, macroporous resin is selected from: polar resin S-8, low pole Resin A B-8 or non-polar resin D101.
3. the medicine of the treatment coronary heart disease of claim 1, is characterized in that, preparation process is:
Step 1, Radix Salviae Miltiorrhizae adds the alcohol reflux 1-5 hour of 2-10 times amount 80% ~ 100%, filters, the medicinal residues ethanol of 2-10 times amount 80% ~ 100%, reflux, extract, 1-5 hour, filters, and medicinal residues are used for salvianolic acid B and extract, filtrate is concentrated into 0.2-1 times of medical material amount, leaves standstill, and filters; Precipitation is dry, obtains Part I tanshinone IIA extract; Macroporous resin on filtrate, 60-85% ethanol elution, eluent discards, then uses 85-100% ethanol elution, collect eluent, be concentrated into alcohol content 65-85%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone IIA extract, and two parts merge, and obtain tanshinone IIA extract;
Step 2, gets step 1 Radix Salviae Miltiorrhizae alcohol extraction medicinal residues and adds 2-10 times amount 30-60% alcohol reflux 1-6 hour, filters, remaining medicinal residues add 2-10 times amount 50-70% alcohol reflux 1-6 hour, and filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 1-3, leave standstill, filter, filtrate crosses macroporous resin, washes with water successively, 10-20% ethanol elution, finally uses 40-70% ethanol elution, collects 40-70% ethanol elution, concentrated, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds alcohol reflux 1-2 time of 5-10 times of 60-80%, each extraction time 0.5-3 hour, extracting liquid filtering, filtrate is concentrated into without alcohol taste, adds the distilled water of 1-3 times of medical material amount, upper macroporous resin, first wash with water, eluent discards, then uses 40-60% ethanol elution, collect alcohol eluen, concentrated, dry, obtain Radix Notoginseng extract;
Step 4, medicinal residues after step 2 alcohol extraction, the aqueous alkali that first time adds 6-12 times amount pH7-8 decocts 1-3 hour, and second time adds 6-12 times amount soak by water 0.5-2 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 50%-75%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 55%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone IIA extract of step 1, salvianolic acid B extract, Radix Notoginseng extract is suspended in the pre-PEG-6000 melted successively; Radix Salviae Miltiorrhizae extractum adds water mix homogeneously; Said two devices mix homogeneously; Add Borneolum Syntheticum again, mixing; Material temperature is 60-100 DEG C; The temperature of liquid paraffin is 0-10 DEG C, makes drop pill;
Wherein, described in step 1 to step 3, macroporous resin is selected from: polar resin S-8, low pole Resin A B-8 or non-polar resin D101.
4. the medicine of the treatment coronary heart disease of claim 1, is characterized in that, preparation process is:
Step 1, Radix Salviae Miltiorrhizae adds the alcohol reflux 2 times of 3-5 times amount 95%, each 1-2 hour, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 0.2-0.6 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I tanshinone IIA extract; Macroporous resin AB-8 on filtrate, 70% ethanol elution, eluent discards, then uses 95% ethanol elution, collect eluent, be concentrated into alcohol content 80%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone IIA extract, and two parts merge, and obtain tanshinone IIA extract;
Step 2, gets step 1 Radix Salviae Miltiorrhizae alcohol extraction medicinal residues, adds the alcohol reflux 2 times of 4-6 times amount 40-60%, each 1-2 hour, filter, filtrate is concentrated into without alcohol, lets cool to less than 10 DEG C, add dilute hydrochloric acid adjust ph 1.8-2.0, cold preservation leaves standstill more than 12 hours, filters, upper AB-8 macroporous resin eluting, first wash with water, eluent discards; Wash with 15% ethanol, eluent discards again; Finally wash with 50% ethanol, collect 50% ethanol elution, concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds the alcohol reflux 2 times of 5-10 times of 60-80%, each extraction time 1-2 hour, extracting liquid filtering, filtrate is concentrated into without alcohol taste, adds the distilled water of 1-3 times of medical material amount, upper macroporous resin AB-8, first wash with water, eluent discards, then uses 40-60% ethanol elution, collect alcohol eluen, concentrated, dry, obtain Radix Notoginseng extract;
Step 4, medicinal residues after step 2 alcohol extraction, the aqueous alkali that first time adds 6-12 times amount pH7-8 decocts 1-3 hour, and second time adds 8 times amount soak by water 1 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 60%-70%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 70%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone IIA extract of step 1, salvianolic acid B extract, Radix Notoginseng extract is suspended in the pre-PEG-6000 melted successively; Radix Salviae Miltiorrhizae extractum adds water mix homogeneously; Said two devices mix homogeneously; Add Borneolum Syntheticum again, mixing; Material temperature is 60-100 DEG C; The temperature of liquid paraffin is 5-10 DEG C, makes drop pill.
5. the medicine of the treatment coronary heart disease of claim 1, is characterized in that, preparation process is:
Step 1, Radix Salviae Miltiorrhizae adds 5 times amount 95% ethanol, reflux, extract, 2 hours, filters, medicinal residues 3 times amount 95% ethanol, reflux, extract, 1 hour, filters, and medicinal residues are used for salvianolic acid B and extract, and filtrate is concentrated into 0.4-0.5 times of medical material amount, leave standstill, and filter; Precipitation is dry, obtains Part I tanshinone IIA extract; AB-8 macroporous resin on filtrate, 70% ethanol elution, eluent discards, and continues to use 95% ethanol elution, collect eluent, be concentrated into alcohol content 80%, leave standstill, filter, precipitation drying under reduced pressure, obtains Part II tanshinone IIA extract, and two parts merge, and obtain tanshinone IIA extract
Step 2, gets step 1 alcohol extraction medicinal residues, adds 3 times amount 20% alcohol reflux 1 hour, filter, medicinal residues add 4 times amount 50% alcohol reflux 1 hour, filter, filtrate is concentrated into without alcohol, let cool to less than 10 DEG C, add dilute hydrochloric acid to medicinal liquid pH value 1.8-2.0, cold preservation leaves standstill more than 12 hours, filter, upper AB-8 macroporous resin, first wash with water, eluent discards; Wash with 15% ethanol, eluent discards again; Finally wash with 50% ethanol, collect 50% ethanol washing liquid, less than 60 DEG C concentrating under reduced pressure, dry, obtain salvianolic acid B extract;
Step 3, Radix Notoginseng adds 8 times amount 70% alcohol reflux 2 hours, and remaining medicinal residues add 6 times amount 70% alcohol reflux 1 hour again, extracting liquid filtering, is concentrated into without alcohol taste, adding distil water to 2 times medical material amount, upper AB-8 macroporous resin, first wash with water, eluent discards, then uses 50% ethanol elution, collect 50% ethanol elution, concentrating under reduced pressure, dry, obtain Radix Notoginseng extract;
Step 4, medicinal residues after step 2 alcohol extraction, the aqueous alkali that first time adds 8 times amount pH7-8 decocts 2 hours, and second time adds 8 times amount soak by water 1 hour, obtains extracting solution, extracting solution concentrates, add ethanol to medicinal liquid alcohol content 60%-70%, leave standstill more than 12 hours, separation of supernatant, reclaim ethanol, receive cream to pol 70%-75%, obtain Radix Salviae Miltiorrhizae extractum;
Step 5, the tanshinone IIA extract obtained after said extracted, salvianolic acid B extract, Radix Notoginseng extract is suspended in the pre-PEG-6000 melted successively; Radix Salviae Miltiorrhizae extractum adds water mix homogeneously; Said two devices mix homogeneously; Add Borneolum Syntheticum again, mixing; Material temperature is 60-100 DEG C; The temperature of liquid paraffin is 5-10 DEG C, makes drop pill.
6. the medicine of claim 1-5 any one treatment coronary heart disease, it is characterized in that, wherein the auxiliary ratio of step 5 medicine is 1:4.0.
7. the application of the medicine of claim 1 in the medicine of a kind of resisting coronary heart disease of preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910070686.0A CN102028746B (en) | 2009-09-29 | 2009-09-29 | Drug for treating coronary heart disease and extraction method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910070686.0A CN102028746B (en) | 2009-09-29 | 2009-09-29 | Drug for treating coronary heart disease and extraction method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102028746A CN102028746A (en) | 2011-04-27 |
| CN102028746B true CN102028746B (en) | 2014-12-24 |
Family
ID=43882556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910070686.0A Active CN102028746B (en) | 2009-09-29 | 2009-09-29 | Drug for treating coronary heart disease and extraction method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102028746B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103923043B (en) * | 2013-01-15 | 2018-11-09 | 天津天士力现代中药资源有限公司 | A method of effectively preparing tanshin polyphenolic acid B extract |
| CN103923042B (en) * | 2013-01-15 | 2018-11-09 | 天津天士力现代中药资源有限公司 | The preparation method of tanshin polyphenolic acid B extract |
| CN104224726B (en) * | 2013-06-17 | 2018-04-03 | 天士力医药集团股份有限公司 | A kind of preparation method of traditional Chinese medicine pellet |
| CN108403882B (en) * | 2018-04-25 | 2021-06-04 | 四川光大制药有限公司 | Salvia miltiorrhiza composition for treating coronary heart disease and preparation method thereof |
| CN112007005A (en) * | 2020-09-10 | 2020-12-01 | 金华市人民医院 | Tanshinone sustained-release dropping pill for treating coronary heart disease and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1596920A (en) * | 2003-09-19 | 2005-03-23 | 天津天士力制药股份有限公司 | A kind of pharmaceutical composition for treating heart disease and its preparation method and application |
| CN1670019A (en) * | 2004-03-17 | 2005-09-21 | 天津天士力现代中药资源有限公司 | Process for extracting tanshinone |
| CN1714819A (en) * | 2004-06-30 | 2006-01-04 | 天津天士力制药股份有限公司 | Medicinal composition for treating coronary heart disease |
| CN101348474A (en) * | 2007-07-20 | 2009-01-21 | 西安鸿生生物技术有限公司 | Method for preparing salvianolic acid B and tanshinol from Salvia miltiorrhiza stem |
| CN101411745A (en) * | 2007-10-15 | 2009-04-22 | 博仲盛景医药技术（北京）有限公司 | Antibiotic tanshinone extract, preparation method thereof, use and products produced thereby |
-
2009
- 2009-09-29 CN CN200910070686.0A patent/CN102028746B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1596920A (en) * | 2003-09-19 | 2005-03-23 | 天津天士力制药股份有限公司 | A kind of pharmaceutical composition for treating heart disease and its preparation method and application |
| CN1670019A (en) * | 2004-03-17 | 2005-09-21 | 天津天士力现代中药资源有限公司 | Process for extracting tanshinone |
| CN1714819A (en) * | 2004-06-30 | 2006-01-04 | 天津天士力制药股份有限公司 | Medicinal composition for treating coronary heart disease |
| CN101348474A (en) * | 2007-07-20 | 2009-01-21 | 西安鸿生生物技术有限公司 | Method for preparing salvianolic acid B and tanshinol from Salvia miltiorrhiza stem |
| CN101411745A (en) * | 2007-10-15 | 2009-04-22 | 博仲盛景医药技术（北京）有限公司 | Antibiotic tanshinone extract, preparation method thereof, use and products produced thereby |
Non-Patent Citations (2)
| Title |
|---|
| 国家药典委员会.复方丹参滴丸.《中华人民共和国药典 2005年版 一部》.化学工业出版社,2005,(第1版),528. * |
| 国家药典委员会.复方丹参片.《中华人民共和国药典 2005年版 一部》.化学工业出版社,2005,(第1版),527. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102028746A (en) | 2011-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102028746B (en) | Drug for treating coronary heart disease and extraction method | |
| WO2016107579A1 (en) | Preparation and application of flavonol as brain-targeting synergist | |
| CN102526186A (en) | Medicinal composition for preventing and treating cardiovascular diseases and application thereof | |
| CN102028747B (en) | Drug for treating coronary heart disease and extraction method | |
| CN102028738B (en) | Medicament for treating coronary heart disease and preparation thereof | |
| CN102028737B (en) | Drug for treating coronary heart disease | |
| CN104173451A (en) | Application of natural pharmaceutical composition in blood glucose-reducing drugs and health food | |
| CN104857154A (en) | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor | |
| WO2011026259A1 (en) | Pharmaceutical compositon for anti-thrombotic diseases, its preparation method and use | |
| CN102028748A (en) | Drug for treating coronary heart disease and extraction process | |
| CN102028743B (en) | Medicament for treating coronary heart disease and preparation method thereof | |
| CN102726708A (en) | Health-care food for lowering blood pressure | |
| CN1985917B (en) | Medicine composition for reducing blood sugar, reducing blood fat and controlling diabetes complication | |
| CN102028745B (en) | Drug for treating coronary heart disease and preparation process | |
| CN102028739B (en) | Drug for treating coronary heart disease and preparation method thereof | |
| CN102028834B (en) | Compound Longxueji preparation and preparation method thereof | |
| CN102028744B (en) | Drug for treating coronary heart disease and preparation method | |
| CN102028742B (en) | Drug for treating coronary heart disease and extraction method thereof | |
| CN102028741B (en) | Medicament for treating coronary heart disease and extraction thereof | |
| CN105326872A (en) | Preparation method for herba patriniae extract with therapeutical effect on ulcerative colitis | |
| CN105535070A (en) | Medicine composition for treating diabetes and preparation method and application thereof | |
| CN100486601C (en) | Application of alcohol extract of spanishneedles herb in preparing medicine for preventing and treating non-alcoholic fatty liver | |
| CN107334795A (en) | Application of the Chinese trumpet creeper general flavone as sole active agent in preparing treatment Streptozotocin and causing diabetes medicament | |
| CN100427115C (en) | Effective part and preparation method of traditional Chinese medicine paeonol for treating cardiovascular disease | |
| CN100411641C (en) | Application of a kind of dropping pill in preparation of medicine for treating aspirin resistance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |